VIVANI MEDICAL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.62 USD | -0.61% |
|
-10.00% | +58.82% |
| Mar. 26 | Vivani Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Mar. 06 | Vivani Medical, Inc. Appoints Daniel Bradbury to Its Board of Directors | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 89.06M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.24
x | P/E ratio 2025 * |
-2.89
x | Employees | 44 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.43% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.61% | ||
| 1 week | -10.00% | ||
| 1 month | -12.43% | ||
| 3 months | +60.40% | ||
| 6 months | +55.77% | ||
| Current year | +58.82% |
1 week
1.61
1.72
1 month
1.612.22
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | - | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1.62 | -0.61% | 39,436 |
| 24-04-29 | 1.63 | -.--% | 62,937 |
| 24-04-26 | 1.63 | -3.83% | 117,480 |
| 24-04-25 | 1.695 | -2.02% | 92,357 |
| 24-04-24 | 1.73 | -3.89% | 53,869 |
End-of-day quote Nasdaq, April 29, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.62
USD
Average target price
8
USD
Spread / Average Target
+393.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.82% | 89.06M | |
| +12.37% | 128B | |
| -6.93% | 10.69B | |
| +2.17% | 8.93B | |
| +18.79% | 7.32B | |
| +20.77% | 4.82B | |
| +6.97% | 3.4B | |
| -1.41% | 3.03B | |
| -5.07% | 2.23B | |
| -4.22% | 2.13B |
- Stock Market
- Equities
- VANI Stock
